Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Top 5 Contagion® News Articles from January 2017

FEB 03, 2017 | CONTAGION EDITORIAL STAFF
#4 Genital HSV Vaccine Provides Powerful Protection in Preclinical Trials
 
Around the world, about half a billion individuals are infected with herpes simplex virus type 2 (HSV-2), the virus that most commonly causes genital herpes. With a number this staggering, researchers around the world have been channeling their efforts into the development of a safe and effective vaccine that will put an end to this global pandemic once and for all.
 
None of the past vaccine candidates have been successful, but a new trivalent vaccine coming from scientists at the Perelman School of Medicine at the University of Pennsylvania may be the one that will change it all. In preclinical tests, the trivalent vaccine—which produces antibodies that fight three different parts of the virus—proved to provide “powerful protection” in preclinical trials, according to a recent press release.
 
According to senior investigator Harvey M. Friedman, MD, professor of Infectious Diseases at Penn, “It’s a novel strategy, and it works beautifully. I know of no other HSV2 vaccine candidate with published results that are as promising as this study.”  
 
Continue reading the full article here.
 
 


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x